SCHEDULE: Janus Henderson Boosts Soleno Therapeutics Stake to 11.4%

Janus Henderson Group plc has filed an amendment to its Schedule 13G, reporting an increased beneficial ownership of 11.4% in Soleno Therapeutics, Inc. as of September 30, 2025.

Summary

• Janus Henderson Group plc, a Jersey-based parent holding company and investment adviser, has filed an Amendment No. 7 to its Schedule 13G regarding its ownership in Soleno Therapeutics, Inc.
• As of September 30, 2025, Janus Henderson Group plc beneficially owns 6,056,339 shares of Soleno Therapeutics' Common Stock.
• This represents 11.4% of the class of securities.
• The reporting person holds shared voting power and shared dispositive power over all 6,056,339 shares.
• Janus Henderson Group plc's indirect subsidiary, JHIUS, is deemed to be the beneficial owner of 5,971,547 shares, representing 11.2% of the class.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as a major institutional investor is maintaining a significant stake, indicating confidence. However, it's a routine disclosure without new operational or financial news from the issuer.

Positives

• A significant institutional investor, Janus Henderson Group plc, maintains a substantial stake (11.4%) in Soleno Therapeutics, indicating continued confidence in the company's long-term prospects.
• The filing explicitly states that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control, suggesting a passive, supportive investment.

Negatives

• No specific negative information regarding Soleno Therapeutics is contained within this beneficial ownership report.

Risks

• This filing does not detail specific risks for Soleno Therapeutics, Inc. beyond the inherent risks associated with any publicly traded company.

Future Outlook

This filing is a beneficial ownership report and does not contain any forward-looking statements or guidance from Soleno Therapeutics, Inc. or Janus Henderson Group plc regarding the issuer's future performance.

Industry Context

This filing reflects a significant institutional investor's continued stake in a biotechnology or pharmaceutical company. Large, passive stakes by asset managers like Janus Henderson are common and often signal long-term investment strategies rather than active involvement in company operations, aligning with typical industry investment patterns for established funds.

Comparison to Industry Standards

• Janus Henderson Group plc's 11.4% stake in Soleno Therapeutics is a substantial position for an institutional investor, placing it among the top shareholders. For comparison, similar biotech companies often see institutional ownership ranging from 50% to 90%, with individual funds holding anywhere from 1% to over 15% depending on their investment mandates and the company's market capitalization and growth stage. This level of ownership by Janus Henderson is consistent with a significant, but passive, long-term investment in a company like Soleno Therapeutics.

Stakeholder Impact

• Shareholders: The continued significant ownership by a major institutional investor like Janus Henderson Group plc may be viewed positively, potentially signaling stability and long-term confidence in Soleno Therapeutics.
• Company Management: The passive nature of the investment (no intent to influence control) suggests that management can continue to execute its strategy without immediate pressure from this particular shareholder.

Key Dates

Recommendation

This Schedule 13G filing primarily reports an updated beneficial ownership stake by a major institutional investor. While the continued significant stake (11.4%) by Janus Henderson Group plc can be seen as a vote of confidence, it does not provide new fundamental information about Soleno Therapeutics' operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The filing indicates a passive investment, not an activist one. Therefore, a 'hold' recommendation is appropriate, pending further operational or financial news from the company itself.

Keywords

Soleno Therapeutics, Janus Henderson Group, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, SNDX, Investment Adviser, Holding Company